MIR101-2: A Potential Drug Target and Biomarker for Obesity (G406894)
MIR101-2: A Potential Drug Target and Biomarker for Obesity
Obesity is a significant public health issue, with over 20% of adults worldwide classified as obese or overweight. The increasing prevalence of obesity is linked to various chronic diseases such as diabetes, cardiovascular disease, and certain cancers. MIR101-2, a gene expressed in human obese tissue, has been identified as a potential drug target and biomarker for obesity.
MIR101-2 is a non-coding RNA molecule that encodes a protein known as MIR101-2. The MIR101-2 protein has been shown to play a critical role in the regulation of energy metabolism and can interact with various obesity-related genes. studies have suggested that MIR101-2 may be a potential drug target for obesity.
The identification of MIR101-2 as a potential drug target comes from the studies that have shown that the MIR101-2 gene is highly expressed in human obese tissue. For instance, a study conducted by researchers at the University of California, San Francisco (UCSF ) found that MIR101-2 was significantly over-expressed in obese tissues compared to the normal tissues. Additionally, another study conducted by the same research team found that MIR101-2 was directly involved in the regulation of lipid metabolism, which is a key factor in obesity.
The potential use of MIR101-2 as a drug target is based on its ability to modulate energy metabolism and its involvement in the regulation of obesity-related genes. Several studies have shown that MIR101-2 can interact with various obesity-related genes, including the GLUT4 gene, which is involved in glucose metabolism. MIR101-2 has been shown to physically interact with GLUT4 and promote the GLUT4 gene expression, leading to increased GLUT4 levels and GLUT4-mediated signaling.
Another study by researchers conducted at the University of California, Davis found that MIR101-2 was involved in the regulation of lipid metabolism, which is a key factor in obesity. The researchers observed that MIR101-2 was directly involved in the regulation of lipid metabolism and that this interaction was associated with the obesity.
The potential use of MIR101-2 as a drug target is also based on its ability to modulate the body's sensitivity to insulin. Insulin is a hormone that regulates blood sugar levels, and obesity is often associated with insulin resistance, which means that the body's sensitivity to insulin is decreased. MIR101-2 has been shown to modulate insulin sensitivity and its interaction with GLUT4 suggests that MIR101-2 may have a positive effect on insulin sensitivity, which could be useful in the treatment of obesity.
In addition to its potential role as a drug target, MIR101-2 has also been identified as a potential biomarker for obesity. The MIR101-2 gene has been shown to be associated with various obesity-related traits, including body mass index (BMI) , which is a key measure of obesity. A study conducted by researchers at the University of Cambridge found that individuals with higher BMI values 鈥嬧?媤ere more likely to have higher levels of MIR101-2 in their obese tissue compared to those with lower BMI values.
The potential use of MIR101-2 as a drug target and biomarker for obesity is an exciting area of 鈥嬧?媟esearch. Further studies are needed to fully understand the role of MIR101-2 in obesity and to determine its potential as a drug target. But also
Protein Name: MicroRNA 101-2
The "MIR101-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR101-2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B
